Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Holocene Advisors LP

Holocene Advisors LP grew its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 8.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,954,528 shares of the company’s stock after purchasing an additional 158,451 shares during the period. Holocene Advisors LP’s holdings in Vera Therapeutics were worth $86,390,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of VERA. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Vera Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after acquiring an additional 350 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in Vera Therapeutics in the 2nd quarter valued at $135,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Vera Therapeutics in the second quarter valued at about $163,000. Cetera Advisors LLC purchased a new position in Vera Therapeutics in the first quarter valued at about $235,000. Finally, Quarry LP acquired a new position in shares of Vera Therapeutics during the second quarter worth about $235,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 15,625 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the completion of the sale, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. This represents a 4.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Beth C. Seidenberg sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $48.03, for a total transaction of $720,450.00. Following the transaction, the director now owns 131,553 shares in the company, valued at $6,318,490.59. This represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 89,927 shares of company stock worth $3,800,796 in the last three months. 21.70% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on VERA shares. Evercore ISI upgraded Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. JPMorgan Chase & Co. lifted their price objective on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $107.00 target price on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Wells Fargo & Company initiated coverage on shares of Vera Therapeutics in a report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price target for the company. Finally, Guggenheim boosted their price objective on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Monday, October 28th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $59.22.

Vera Therapeutics Stock Performance

Shares of NASDAQ VERA opened at $49.95 on Monday. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm’s 50-day moving average price is $44.21 and its two-hundred day moving average price is $39.77. Vera Therapeutics, Inc. has a 52-week low of $13.09 and a 52-week high of $51.61. The stock has a market capitalization of $3.16 billion, a P/E ratio of -19.06 and a beta of 1.03.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.21). As a group, sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.